# Kidney Infection Market

> Kidney Infection Market Research Report Information By Diagnosis (Dipstick Urine Test, Imaging Test, Treatment (Medication, Antibiotics, Nsaids, Dialysis, Kidney Transplant), End User (Hospitals & Clinics, Nephrology Center, Research Institutes) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.6%
- **2024:** $ 4.91 Billion
- **2025:** $ 5.48 Billion
- **2035:** $ 16.42 Billion
- **Key Players:** Johnson & Johnson (US), Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), AstraZeneca (GB), Novartis (CH), Gilead Sciences (US), AbbVie (US), Sanofi (FR)

**Report ID:** MRFR/LS/3754-HCR · **Pages:** 110 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/kidney-infection-market-5192

---

## Market Summary

## **Kidney Infection Market Overview**

Kidney Infection Market Size was valued at USD 4.4 Billion in 2023. The Global Kidney Infection industry is projected to grow from USD 4.79 Billion in 2024 to USD 10.67 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.5% during the forecast period (2024 - 2032).

The blood test is performed to make sure that the kidneys are functioning normally. The urine test, called a urinalysis, detects any abnormal cells or proteins that relate to a kidney problem. If the blood and urine tests are normal, then no other tests are required. In some cases, these infections are diagnosed when a person undergoes an ultrasound examination or CT scan of the abdomen for some other reason. Additionally, the urologist may suggest an X-ray examination called “Voiding Cystourethrogram”.

Increasing prevalence of kidney infections, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the kidney infection market. Furthermore, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases are likely to fuel the kidney infection market growth during the forecast period. Moreover, increasing geriatric population is projected to boost the kidney infection market growth. Established market players in the developed countries lead the globalization by pushing new products and services into the developing countries and emerging economies.

However, higher treatment cost may hinder the kidney infection market growth over the review period.

As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Kidney disease is often referred to as a “silent disease” as there are no symptoms in its early stages and can go undetected. Chronic kidney disease (CKD) is a global health burden risk factor for cardiovascular disease (CVD). High blood pressure and diabetes are the main causes of CKD. The high economic cost to health systems and decreased productivity are the major drawbacks of kidney diseases. NIDDK also stated that the overall prevalence of Chronic Kidney Disease (CKD) in the general population is approximately 14%.

It also stated that in 2013, Medicare spending for patients with CKD aged 65 and older exceeded USD 50 billion, which accounted for 20% of total Medicare spending in this age group. Over 70% of the Medicare spending for CKD patients aged 65 and older was incurred by those who also had diabetes, congestive heart failure, or both.

**Intended Audience**

## **Kidney Infection Market Segmentations**

The kidney infection market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of the diagnosis, kidney infection market is segmented into dipstick urine test and imaging test. The imaging test is further segmented into ultrasound, CT scan, voiding cystourethrogram, and others.

The treatment segment is divided into medication, dialysis, kidney transplant, and others. The medication is further segmented into antibiotics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Based on the end user, kidney infection market is segmented into hospitals & clinics, nephrology center, research institutes, and others.

## **Kidney Infection Market Regional Analysis**

The Americas dominate the kidney infection market owing to the availability of technologically advanced medical devices for diagnosis and treatment of kidney infection such as dialysis machine, increasing patient population for a kidney infection, increasing government support for research & development, and high health care spending. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the kidney infection market in this region.   

The European region is exhibiting flourishing growth owing to the increasing emphasis on the development of new drugs, rising government support for research & development, and availability of funds for research. Rising number of specialty services offered by various healthcare providers in Europe also accelerate the growth of the kidney infection market. For instance, developed economies such as Germany and France are increasing investment in the healthcare domain and are focusing more on the hospital infrastructure.  

The Asia Pacific is the fastest growing kidney infection market owing to the presence of rapidly developing healthcare technology and high healthcare expenditure. Moreover, increasing patient population in countries such as India is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may speed up the market growth in this region.    

However, the Middle East & Africa holds the least share of the kidney infection market due to less availability of funds, limited medical facilities, and unavailability technologically advanced medical devices.

## **Kidney Infection Market Key Players**

## Market Drivers

### Emergence of Targeted Therapies

The emergence of targeted therapies is reshaping the landscape of the Kidney Infection Market. Recent research has focused on developing medications that specifically address the underlying causes of kidney infections, rather than merely alleviating symptoms. This shift towards personalized medicine is likely to enhance treatment efficacy and patient compliance. Market forecasts indicate a growing demand for these advanced therapeutic options, as patients and healthcare providers seek more effective solutions. Additionally, the increasing prevalence of antibiotic resistance highlights the need for alternative treatment strategies, further driving interest in targeted therapies. As pharmaceutical companies invest in research and development, the Kidney Infection Market is poised for significant transformation, with a focus on innovative and effective treatment modalities.

### Growing Awareness of Kidney Health

There is a notable increase in public awareness regarding kidney health, which serves as a catalyst for the Kidney Infection Market. Educational campaigns and initiatives by health organizations have highlighted the importance of kidney function and the risks associated with infections. This heightened awareness is leading to more individuals seeking medical advice and preventive measures, thereby increasing the demand for diagnostic and therapeutic options. Market data indicates that regions with active awareness programs report higher rates of early diagnosis and treatment of kidney infections. Consequently, this trend is likely to drive growth in the Kidney Infection Market as healthcare providers respond to the rising demand for services and products aimed at maintaining kidney health.

### Advancements in Diagnostic Technologies

Technological innovations in diagnostic tools are significantly influencing the Kidney Infection Market. Enhanced imaging techniques, such as ultrasound and CT scans, allow for more accurate and timely diagnosis of kidney infections. Additionally, the development of rapid urine tests and biomarkers has improved the ability to detect infections early, leading to better patient outcomes. The market for diagnostic devices is projected to grow, driven by the increasing need for efficient and precise diagnostic methods. As healthcare systems adopt these advanced technologies, the Kidney Infection Market is expected to expand, with a focus on integrating these innovations into routine clinical practice. This trend not only enhances patient care but also encourages further research and development in the field.

### Increasing Prevalence of Kidney Infections

The rising incidence of kidney infections is a primary driver of the Kidney Infection Market. Factors such as lifestyle changes, increased rates of diabetes, and urinary tract infections contribute to this trend. According to health statistics, kidney infections affect millions annually, with a notable increase in cases among older adults and individuals with compromised immune systems. This growing patient population necessitates the development of effective treatment options, thereby propelling market growth. Furthermore, the economic burden associated with kidney infections, including hospitalizations and long-term care, underscores the urgency for innovative solutions within the Kidney Infection Market. As awareness of kidney health continues to rise, healthcare providers are likely to prioritize the prevention and management of these infections, further stimulating market demand.

### Rising Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is a crucial driver for the Kidney Infection Market. Governments and private entities are increasingly allocating resources to enhance healthcare facilities, particularly in underserved areas. This expansion includes the establishment of specialized clinics and hospitals equipped to manage kidney-related conditions. As healthcare access improves, more patients are likely to receive timely diagnosis and treatment for kidney infections. Furthermore, the integration of advanced medical technologies within these facilities is expected to enhance the quality of care. Market analysts suggest that this trend will lead to a more robust Kidney Infection Market, as improved infrastructure facilitates better patient management and encourages the development of innovative treatment options.

## Future Outlook

The Kidney Infection Market is projected to grow at an 11.6% CAGR from 2025 to 2035, driven by rising incidence rates, advancements in diagnostics, and increased healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) Investment in AI-driven diagnostic tools for early detection Expansion of targeted antibiotic therapies to combat resistance

By 2035, the Kidney Infection Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Diagnosis: Dipstick Urine Test (Largest) vs. Imaging Test (Fastest-Growing)

Within the Diagnosis segment of the Kidney Infection Market, the dipstick urine test holds the largest market share, primarily due to its ease of use and cost-effectiveness. This test is widely adopted in clinical settings for its ability to quickly assess kidney function and detect infections through the presence of protein, nitrites, and leukocytes in urine samples. Imaging tests, while traditionally more resource-intensive and costly, have gained traction as they provide comprehensive insights into kidney structure and complications associated with infections. As the healthcare sector continues to advance, the growth trends point to an increasing reliance on imaging tests as technology improves. The emergence of advanced imaging modalities, such as ultrasound and CT scans, is driving their adoption for diagnosing kidney infections. These tests offer enhanced accuracy, leading to better patient outcomes and increasing demand among healthcare practitioners, positioning imaging tests as the fastest-growing segment in comparison to the dipstick urine test.

Diagnostic Methods: Dipstick Urine Test (Dominant) vs. Imaging Test (Emerging)

The dipstick urine test is considered the dominant diagnostic method within the Kidney Infection Market due to its established presence and ease of use, allowing for quick and accessible testing in various clinical settings. It is valuable for initial assessments and routine screenings, making it a preferred choice among healthcare providers. On the other hand, imaging tests represent the emerging segment of this market, driven by technological advancements that improve diagnostic accuracy and expand the types of conditions detectable through imaging. While imaging tests tend to be more resource-intensive, their growing adoption is propelled by rising patient needs for precise diagnostics, complex cases, and the medical community's focus on comprehensive care.

### By Treatment: Medication (Largest) vs. Dialysis (Fastest-Growing)

Within the Kidney Infection Market, treatment modalities are predominantly segmented into Medication, Dialysis, and Kidney Transplant, where Medication holds the largest market share. This method emphasizes pharmacological approaches, utilizing antibiotics and anti-inflammatory drugs to combat kidney infections effectively. Dialysis, on the other hand, represents the fastest-growing segment, reflecting an increasing prevalence of chronic kidney diseases and the rising need for renal replacement therapies among affected populations. As a result, the competition in the dialysis market is intensifying, with innovative technologies continually enhancing treatment efficacy. The growth trends in the Kidney Infection Market are significantly influenced by advancements in medical technologies, awareness about kidney health, and the rising incidence of kidney-related disorders. Patients and healthcare providers are increasingly opting for treatments that not only promise effectiveness but also minimize side effects. As such, the demand for more comprehensive and personalized medication regimes is on the rise. Moreover, the aging global population contributes to increasing kidney infections, further spurring growth for both Medication and Dialysis treatments. This dual demand for effective therapeutic solutions underscores a dynamic shift in patient treatment preferences across the segment.

Medication (Dominant) vs. Dialysis (Emerging)

In the Kidney Infection Market, Medication stands out as the dominant treatment modality primarily due to its established role in managing infections through antibiotics and related therapies. This method provides immediate relief and is widely accepted among healthcare professionals. On the other hand, Dialysis, emerging as a crucial treatment option, supports patients with acute kidney failure or those with chronic kidney issues, indicating a shift towards more complex care solutions. The increasing awareness among patients regarding kidney health, combined with the growing prevalence of lifestyle-related kidney diseases, drives the growth of Dialysis. This segment is rapidly evolving, fostering innovations that enhance the overall efficiency and comfort of kidney treatments. As a result, both segments are witnessing robust demand, catering to different aspects of kidney health management.

### By End User: Hospitals & Clinics (Largest) vs. Nephrology Centers (Fastest-Growing)

In the Kidney Infection Market, the end-user segment is primarily dominated by hospitals and clinics, which hold a substantial share due to their extensive reach and capacity to provide comprehensive care. This segment benefits from a steady influx of patients seeking treatment for kidney infections, thanks to increasing awareness and improvements in healthcare access. Nephrology centers, while comparatively smaller in market share, are emerging as significant players, focusing on specialized care for kidney diseases. Their tailored approaches cater to specific needs, propelling their growth in this segment.

Hospitals & Clinics (Dominant) vs. Nephrology Centers (Emerging)

Hospitals and clinics serve as the backbone of the healthcare system for treating kidney infections, characterized by their broad range of services and ability to cater to a large patient base. They are equipped with necessary resources, specialized staff, and advanced technologies for diagnosing and managing kidney health issues. On the other hand, nephrology centers are quickly gaining prominence, with a dedicated focus on kidney care. These centers prioritize specialized treatments and research, allowing them to adapt to evolving patient needs and advancing medical practices. Their growth is driven by an increasing prevalence of kidney diseases and a growing population seeking targeted, expert care.

## Regional Market Share Analysis

### North America : Healthcare Innovation Leader

North America is the largest market for kidney infections, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of kidney diseases, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of innovative treatments and therapies. The United States leads the North American market, with key players such as Johnson & Johnson, Pfizer, and Merck & Co. dominating the landscape. The competitive environment is characterized by continuous innovation and strategic partnerships among pharmaceutical companies. The presence of a well-established healthcare system and high patient awareness contribute to the region's strong market position.

### Europe : Emerging Market Dynamics

Europe is the second-largest market for kidney infections, holding around 30% of the global market share. The region's growth is fueled by an aging population, rising healthcare expenditure, and increasing awareness of kidney health. Regulatory frameworks, such as the European Medicines Agency's guidelines, promote the development and approval of new therapies, enhancing market accessibility and patient care. Leading countries in Europe include Germany, France, and the UK, where major pharmaceutical companies like AstraZeneca and Novartis are actively involved. The competitive landscape is marked by a mix of established players and emerging biotech firms, fostering innovation. Collaborative efforts between public health organizations and private sectors aim to improve treatment outcomes and patient access to care.

### Asia-Pacific : Rapidly Expanding Market

Asia-Pacific is witnessing rapid growth in the kidney infection market, driven by rising healthcare investments and increasing disease prevalence. The region accounts for approximately 20% of the global market share, with countries like China and India leading the charge. Government initiatives aimed at improving healthcare infrastructure and access to treatments are significant growth catalysts, alongside a growing awareness of kidney health among the population. China and India are the primary markets in this region, with a mix of local and international players competing for market share. Companies like Gilead Sciences and AbbVie are expanding their presence, focusing on innovative therapies and partnerships. The competitive landscape is evolving, with an increasing number of startups entering the market, driven by technological advancements and a focus on patient-centric solutions.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually emerging in the kidney infection market, holding about 5% of the global market share. The growth is primarily driven by increasing healthcare investments, rising awareness of kidney diseases, and government initiatives aimed at improving healthcare access. Regulatory bodies are beginning to establish frameworks that support the introduction of new treatments, which is crucial for market development. Countries like South Africa and the UAE are at the forefront of this market, with a growing number of healthcare facilities and increasing patient awareness. The competitive landscape is characterized by a mix of local and international players, with companies like Sanofi making significant inroads. Collaborative efforts between governments and private sectors are essential to address the healthcare challenges in this region and improve patient outcomes.

## Competitive Benchmarking

The Kidney Infection Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for effective treatment options. Key players such as Johnson & Johnson (US), Pfizer (US), and Merck & Co. (US) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovative therapies and advanced drug formulations. These companies are actively pursuing partnerships and collaborations to enhance their product offerings and expand their market reach, thereby shaping a competitive environment that emphasizes both innovation and strategic alliances.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing their supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like AstraZeneca (GB) and Novartis (CH) is significant, as they implement strategies that not only bolster their competitive positioning but also contribute to the overall growth of the market.

In August 2025, Johnson & Johnson (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel antibiotic specifically targeting resistant strains of bacteria associated with kidney infections. This collaboration is likely to enhance Johnson & Johnson's portfolio and address the urgent need for effective treatments in an era of rising antibiotic resistance, thereby reinforcing its market leadership.

In September 2025, Pfizer (US) launched a new digital health platform aimed at improving patient adherence to prescribed kidney infection treatments. This initiative reflects Pfizer's commitment to integrating technology into healthcare, potentially transforming patient management and outcomes. By leveraging digital tools, Pfizer may enhance its competitive edge and foster stronger patient engagement, which is increasingly vital in today's healthcare landscape.

In July 2025, Merck & Co. (US) expanded its clinical trial program for a promising new therapeutic agent targeting kidney infections, focusing on diverse patient populations. This strategic move underscores Merck's dedication to inclusivity in clinical research and its aim to develop treatments that cater to a broader demographic. Such initiatives not only enhance Merck's reputation but also position it favorably in a market that values diversity and comprehensive healthcare solutions.

As of October 2025, current competitive trends in the Kidney Infection Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development and patient care. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains, ultimately shaping a more resilient and responsive market.

## Report Scope

| MARKET SIZE 2024 | 4.91(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 5.48(USD Billion) |
| MARKET SIZE 2035 | 16.42(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Johnson & Johnson (US), Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), AstraZeneca (GB), Novartis (CH), Gilead Sciences (US), AbbVie (US), Sanofi (FR) |
| Segments Covered | Diagnosis |
| Key Market Opportunities | Advancements in telemedicine enhance patient access and management in the Kidney Infection Market. |
| Key Market Dynamics | Rising prevalence of kidney infections drives demand for innovative treatment options and enhanced patient care solutions. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Kidney Infection Market as of 2024?**
A: The Kidney Infection Market was valued at 4.91 USD Billion in 2024.

**Q: What is the projected market size for the Kidney Infection Market by 2035?**
A: The market is projected to reach 16.42 USD Billion by 2035.

**Q: What is the expected CAGR for the Kidney Infection Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Kidney Infection Market during 2025 - 2035 is 11.6%.

**Q: Which segments are included in the Diagnosis category of the Kidney Infection Market?**
A: The Diagnosis category includes Dipstick urine tests and Imaging tests, each valued at 1.47 USD Billion in 2024.

**Q: What are the key treatment segments in the Kidney Infection Market?**
A: Key treatment segments include Medication, Dialysis, and Kidney transplant, with Medication valued at 2.45 USD Billion in 2024.

**Q: Who are the leading players in the Kidney Infection Market?**
A: Key players include Johnson & Johnson, Pfizer, Merck & Co., and AstraZeneca, among others.

**Q: What is the valuation of the End User segment in the Kidney Infection Market?**
A: The End User segment, which includes Hospitals & clinics, was valued at 2.45 USD Billion in 2024.

**Q: How does the valuation of the Nephrology center segment compare to others?**
A: The Nephrology center segment was valued at 1.5 USD Billion in 2024, indicating its importance in the market.

**Q: What is the projected growth trend for the Kidney Infection Market?**
A: The market is expected to experience substantial growth, reaching 16.42 USD Billion by 2035.

**Q: What role do research institutes play in the Kidney Infection Market?**
A: Research institutes are a vital part of the market, valued at 0.96 USD Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/kidney-infection-market-5192*